Compounds > 8-methylquinoline
Page last updated: 2024-11-05

8-methylquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11910
CHEMBL ID1702610
CHEBI ID48984
SCHEMBL ID256942
MeSH IDM0161078

Synonyms (57)

Synonym
AC-5093
EN300-25427
8-methyl-quinoline
o-toluquinoline
ccris 408
inchi=1/c10h9n/c1-8-4-2-5-9-6-3-7-11-10(8)9/h2-7h,1h
quinoline, 8-methyl-
nsc9409
nsc-9409
611-32-5
8-methylquinoline ,
NCGC00091614-01
CHEBI:48984 ,
einecs 210-264-0
ai3-00849
brn 0111340
8-methylquinoline, 97%
nistc611325
quinoline, 8-methyl- (8ci,9ci)
ai3-0111340
nsc 9409
MLS002303012
smr001307318
FT-0660641
M0419
AKOS001287315
NCGC00091614-02
HMS3039E09
cas-611-32-5
tox21_200341
dtxcid80888
NCGC00257895-01
dtxsid8020888 ,
5-20-07-00405 (beilstein handbook reference)
unii-k97b12j636
k97b12j636 ,
FT-0602149
AC-907/25014270
AM1097
SCHEMBL256942
8-methyl quinoline
8-metyl quinoline
W-204381
CHEMBL1702610 ,
TS-01865
1199266-77-7
methylquinoline, 8-
J-519467
mfcd00006810
Q27121420
quinoline, 8-methyl- pound>>8-methyl-quinoline pound>>o-toluquinoline
BCP27326
STL190850
bdbm50264545
I11487
quinoline, 8-methyl-, labeled with deuterium
Z204013194
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylquinolineAny member of the class of quinolines carrying at least one methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.81020.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency11.57740.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency3.26430.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency68.10160.000221.22318,912.5098AID743042
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.21520.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency60.69570.003041.611522,387.1992AID1159552
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.08200.00419.984825.9290AID504444
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency66.82420.000627.21521,122.0200AID651741
gemininHomo sapiens (human)Potency14.64940.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)IC50 (µMol)100.00000.00701.09812.5000AID1480589
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
double-strand break repair via homologous recombination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
double-strand break repair via nonhomologous end joining26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
response to ethanol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
regulation of proteasomal protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein K63-linked deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metallopeptidase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal ion binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
endopeptidase activator activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
K63-linked deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal-dependent deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosolic proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1480590Antiproliferative activity against human HCT116 cells after 72 hrs by Cell Titer-Glo assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
AID1480589Inhibition of 26S proteasome regulatory subunit RPN11 deubiquitinating activity in human erythrocytes using Ub4-pepOG protein substrate preincubated for 1 hr followed by substrate addition measured after 80 mins by fluorescence polarization assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's1 (7.69)18.2507
2000's3 (23.08)29.6817
2010's6 (46.15)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.78 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index30.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
octane
Octanes: Eight-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. octane : A straight chain alkane composed of 8 carbon atoms.		210alkanexenobiotic
naphthalene
[no description available]		210naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		1.9810ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.1510monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9810barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
benzo(f)quinoline
[no description available]		1.9710
quinoline
[no description available]		6.9710azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
6-methylquinoline
[no description available]		1.9810quinolines
4-methylquinoline
4-methylquinoline: structure given in first source; RN given refers to parent cpd. 4-methylquinoline : A methylquinoline carrying a methyl substituent at position 4.		1.9710methylquinolinemutagen
n-hydroxyphthalimide
N-hydroxyphthalimide: causes contact dermititis		2.4110
8-aminoquinoline
[no description available]		2.1510
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		2.4520metal allergen;
nickel group element atom;
platinum group metal atom
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		2.4110cobalt group element atom
fluorides
[no description available]		2.0710halide anion;
monoatomic fluorine
8-mercaptoquinoline
8-mercaptoquinoline: structure given in first source		2.1510
bortezomib
[no description available]		2.1510amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
alpha-ionone
alpha-ionone: RN given refers to cpd without isomeric designation; structure		210enone;
ionone;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Benign Neoplasms
[description not available]		02.1510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1510
Cancer of Liver
[description not available]		01.9710
Cancer of Lung
[description not available]		01.9710
Experimental Neoplasms
[description not available]		01.9710
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710